Key terms
About DNLI
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DNLI news
Mar 22
4:03pm ET
Denali Therapeutics files to sell 29.29M shares of common stock for holders
Mar 05
4:06am ET
Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and arGEN X (GB:0QW0)
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Mar 01
7:47am ET
Denali Therapeutics (DNLI) Gets a Buy from Oppenheimer
Mar 01
1:00am ET
Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution
Feb 28
7:45am ET
Buy Rating Affirmed for Denali Therapeutics Amid Promising Pipeline and Strategic FDA Engagement
Feb 28
7:35am ET
Buy Rating Affirmed on Denali Therapeutics Amid Promising DNL310 Progress and ETV Technology Potential
Feb 28
7:31am ET
Denali Therapeutics price target lowered to $95 from $105 at H.C. Wainwright
Feb 28
7:06am ET
Buy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash Runway
Feb 28
6:59am ET
Strong Buy Rating for Denali Therapeutics: Financial Stability and Promising Clinical Advancements
Feb 28
6:28am ET
Denali Therapeutics: Strong Buy Rating Backed by Financial Fortitude and Strategic Pipeline Advancements
Feb 27
1:00pm ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)
Feb 27
8:31am ET
Denali Therapeutics to sell 3.24M shares at $17.07 in private placement
Feb 27
8:12am ET
Denali Therapeutics Strengthens R&D with $500M Investment
Feb 27
8:08am ET
Denali Therapeutics expects cash runway to extend into 2028
Feb 27
8:07am ET
Denali Therapeutics reports Q4 EPS (86c), consensus (80c)
Feb 22
7:04am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Feb 22
6:15am ET
Buy Rating on Denali Therapeutics: Anticipating Accelerated FDA Approval with CSF HS Biomarker Breakthrough
Feb 22
1:35am ET
Buy Rating Affirmed for Denali Therapeutics Amid Favorable Biomarker-Based Approval Prospects
Feb 20
6:36pm ET
Denali Therapeutics’ treatment of MPS IIIA granted FDA orphan designation
Feb 20
8:59am ET
Denali Therapeutics ALS study failue ‘clearing event,’ says B. Riley
Feb 20
8:55am ET
Denali continues decline after Sanofi ALS study failure
Feb 19
5:30am ET
Analysts’ Top Healthcare Picks: IQVIA Holdings (IQV), Denali Therapeutics (DNLI)
Feb 16
5:45pm ET
Maintaining Buy on Denali Therapeutics: A Resilient Pipeline Despite Setbacks Offers Favorable Risk-Reward
Feb 16
5:31pm ET
Denali Therapeutics price target lowered to $27 from $32 at Citi
Feb 16
2:25pm ET
Maintaining Buy Rating: Denali Therapeutics’ Long-Term Growth Outlook Despite HIMALAYA Study Setback
Feb 16
8:14am ET
Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues
Feb 09
8:01am ET
Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Illumina (ILMN)
Feb 08
6:20am ET
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)
Feb 07
9:55pm ET
Buy Rating for Denali Therapeutics Backed by Promising DNL310 Clinical Data and Accelerated Approval Potential
Feb 07
8:08am ET
Denali announces data, expansion of BBB-crossing enzyme replacement therapy
No recent news articles are available for DNLI
No recent press releases are available for DNLI
DNLI Financials
Key terms
Ad Feedback
DNLI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DNLI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range